Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550291 | 1.00 | SIGMAR1 (0.46) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL25642148 | 1.00 | SIGMAR1 (0.46) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL2552769 | 0.99 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL2552771 | 0.99 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL2557456 | 0.91 | SIGMAR1 (0.39) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL2557457 | 0.91 | SIGMAR1 (0.39) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL25272743 | 0.90 | HTR2A (0.49) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL25643695 | 0.90 | HTR2A (0.49) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL25642197 | 0.90 | HTR2A (0.49) | SIGMAR1DRD2HTR2AMEN1KMT2A | |
| SCHEMBL25643557 | 0.88 | DRD2 (0.42) | SIGMAR1DRD2HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011121055-A1 | PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY | TOPOTARGET A/S (DK) | 2011-10-06 | — | — | WO | claimed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2011121055-A1 | PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY | TOPOTARGET A/S (DK) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | SIGMAR1 3861/4885DRD2 1634/4885HTR2A 1216/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | SIGMAR1 3950/4885DRD2 1688/4885HTR2A 1275/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | SIGMAR1 3950/4885DRD2 1688/4885HTR2A 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.